Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC).

Authors: Alan Haruo Bryce, Karim Fizazi, Guilhem Roubaud, Scott T. Tagawa, Alice Bernard-Tessier, Diego Teyssonneau, Carole Helissey, Tanya B. Dorff, Dana Rathkopf, Nabil Adra, Joseph Francis O'Donnell, Johan Baeck, Tyler David Ames, Matthew R. Price, Howard I. Scher

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5071

Source: Full article

---

Abstract

5071